Drynol 20 mg tablets
- Name:
Drynol 20 mg tablets
- Company:
A. Menarini Pharmaceuticals Ireland Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/08/20

XPIL
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
1. What Drynol is and what it is used for
1. What Drynol is and what it is used for
2. What you need to know before you take Drynol 20 mg tablets
2. What you need to know before you take Drynol 20 mg tablets
3. How to take Drynol
3. How to take Drynol
4. Possible side effects
4. Possible side effects
5. How to store Drynol
5. How to store Drynol
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
A. Menarini Pharmaceuticals Ireland Ltd

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 18 August 2020 PIL
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
The change is to update the Patient Leaflet by listing serious or life-threatening side effects at the beginning of section 4 - Possible side effects, irrespective of the frequency.
Updated on 21 November 2019 PIL
Reasons for updating
- Change to section 2 - driving and using machines
- Change to section 3 - use in children/adolescents
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
The PIL has been updated regarding use in the paediatric population.
Updated on 21 November 2019 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The SmPC has been updated regarding use in the paediatric population including treatment, warnings and precautions, interactions, side-effects, overdose, pharmacodynamic and pharmacokinetic properties.
Updated on 14 March 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 14 March 2019 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
- Update to section 4.8 of the SmPC, to add the adverse reaction "vomiting" with the frequency not known.
Updated on 17 May 2018 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Update of section 4.8 of the SmPC, to add the adverse reaction “Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, rash, localised oedema/local swelling and erythema)” with a frequency not known.
Updated on 8 May 2018 PIL
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 28 February 2017 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 28 February 2017 SPC
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The following changes (shown in italics) have been made.
Section 4.6 Fertility, pregnancy and lactation
Breast-feeding
The excretion of bilastine in milk has not been studied in humans. "Available pharmacokinetic data in animals have shown excretion of bilastine in milk (see section 5.3)" has been added.
Section 5.3 Preclinical safety data
The following information has been added "In a lactation study, bilastine was identified in the milk of nursing rats administered a single oral dose (20 mg/kg). Concentrations of bilastine in milk were about half of those in maternal plasma. The relevance of those results for humans is unknown"
Updated on 15 December 2016 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
- Section 5.1 Pharmacodynamic properties
- Wording added: A post-authorization study in 146 elderly patients showed no differences in the safety profile with respect to the adult population.
- Section 5.2 Pharmacokinetic properties
- Wording amended: Only limited pharmacokinetic data are available in subjects older than 65 years.
- Administrative (QRD) updates Sections 4.2, 5.1 and 5.2
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Update following results of the Post-Authorisation Safety Study in elderly :
- Section 5.1 Pharmacodynamic properties
- Wording added: A post-authorization study in 146 elderly patients showed no differences in the safety profile with respect to the adult population.
- Section 5.2 Pharmacokinetic properties
- Wording amended: Only limited pharmacokinetic data are available in subjects older than 65 years.
- Administrative (QRD) updates
Sections 4.2, 5.1 and 5.2
Updated on 15 December 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 15 December 2016 PIL
Reasons for updating
- Change to section 6 - date of revision
- Change to section 3 - how to take/use
Updated on 8 December 2015 PIL
Reasons for updating
- Change to date of revision
- Change to improve clarity and readability
- Addition of information on reporting a side effect.
Updated on 8 December 2015 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 28 March 2013 PIL
Reasons for updating
- Change to date of revision
- Change of distributor details
Updated on 16 February 2012 SPC
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The following changes have been made:
- Update to section 5.2 Pharmacokinetic properties to include the results of 2 new pharmacokinetic studies
-
Re-order section 5.2 with subheadings.
Updated on 10 February 2012 PIL
Reasons for updating
- Change to further information section
- Change to date of revision
- Change to improve clarity and readability
Updated on 30 August 2011 PIL
Reasons for updating
- Change to date of revision
- Change to improve clarity and readability
Updated on 5 July 2011 PIL
Reasons for updating
- New PIL for new product
Updated on 5 July 2011 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)